益气康肺方预防新型冠状病毒感染临床观察及试验指标分析

Clinical observation and trial index analysis of the Yiqi Kangfei decoction for the prevention of COVID-19

目的:观察益气康肺方对新型冠状病毒感染确诊病例接触者的临床预防效果及不良反应,为临床选方用药及相关研究提供依据。方法:选取132例新型冠状病毒感染确诊病例密切接触者为研究对象,均按照相关规定单独隔离14 d,隔离期间按照干预治疗方法分为对照组与观察组。对照组进行临床隔离观察。观察组给予益气康肺方,每日1剂,煎取400 mL,分早晚2次温服,连服14 d。观察两组发病情况,比较两组发病率,分析治疗前后白细胞(White Blood Cell,WBC)、淋巴细胞(Lymphocyte,LYM)水平及不良反应的发生情况。结果:观察组新型冠状病毒感染发病率为0.00%(0/66),明显低于对照组的6.06%(4/66),差异有统计学意义(P<0.05);干预后两组外周血WBC、LYM水平较干预前降低(P<0.05),且对照组降低幅度更显著(P<0.05);两组不良反应发生率均为0,差异无统计学意义(P>0.05)。结论:益气康肺方干预新型冠状病毒感染确诊病例接触者的临床效果显著,可降低患者发病风险。有研究发现WBC、LYM水平与发病严重程度和临床预后密切相关,益气康肺方可减少降幅水平,可能为缓解犯病严重程度和改善临床预后中发挥一定的作用。益气康肺方降低新型冠状病毒感染发病风险作用机制可能与细胞免疫有关。

Objective:To observe the clinical preventive efficacy and adverse reactions of the Yiqi Kangfei decoction(益气康肺方)on contacts of confirmed cases of COVID-19(novel coronavirus pneumonia),so as to provide evidence for clinical decoction selection and related research.Methods:A tatol of 132 close contacts of the confirmed COVID-19 cases were selected as the study subjects,who were isolated separately for 14 days according to the relevant regulations.During the isolation period,the subjects were divided into the control group and the observation group according to the clinical intervention methods.The control group was observed in clinical isolation.The observation group was given the Yiqi Kangfei decoction,1 warm dose of 400 mL decoction per day,which was administered twice a day,in the morning and evening,for 14 continuous days.The incidence of COVID-19 in the two groups was observed and compared.The levels of WBC and lymphocyte(LYM)and the occurrence of adverse reactions before and after treatment were analyzed.Results:The incidence of COVID-19 in the observation group was 0.00%(0/66),which was significantly lower than 6.06%(4/66)in the control group,there was statistical significance(P<0.05).After intervention,the levels of peripheral blood WBC and LYM in the two groups were decreased compared with those before intervention(P<0.05),and those in the control group were decreased significantly(P<0.05).The incidence of adverse reactions in both groups was 0.00%,which was of no statistical significance(P>0.05).Conclusion:The Yiqi Kangfei decoction has a remarkable clinical effect on the contacts of confirmed cases of COVID-19,and it can reduce the morbidity of subjects.Relevant studies have found that the levels of WBC and LYM are closely related to the severity of the disease and clinical prognosis.The Yiqi Kangfei decoction can reduce its decline level,and may play a role in alleviating the severity of the disease and improving the clinical prognosis.